Management of Patients under Treatment with Monoclonal Antibodies and New Biological Therapies

Objective: The aim of this study is to know the biological therapy drugs that are related to adverse events, what dental treatments are associated with the appearance of these events, their severity, and how they are resolved. Study design: Analysis of cases described in the literature on patients u...

Full description

Saved in:
Bibliographic Details
Published in:Applied sciences 2021-06, Vol.11 (11), p.4865
Main Authors: Amigo-Basilio, Marta, Álvarez-González, Covadonga, Cobo-Vázquez, Carlos, Leco-Berrocal, Isabel, Sáez-Alcaide, Luis Miguel, Méniz-García, Cristina
Format: Article
Language:English
Subjects:
antiangiogenic agent
Antibiotics
Biological products
Cytokines
denosumab
Drugs
Erythema
Immunotherapy
Infections
Jaw
Monoclonal antibodies
monoclonal antibody
Oral cavity
osteonecrosis of the jaw
Patients
Physiology
Proteins
Side effects
stomatitis
target therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective: The aim of this study is to know the biological therapy drugs that are related to adverse events, what dental treatments are associated with the appearance of these events, their severity, and how they are resolved. Study design: Analysis of cases described in the literature on patients undergoing treatment with biological therapies who have developed adverse effects associated with these drugs. Results: Of the 62 articles reviewed, 49 describe 68 cases of MRONJ, most of which appeared in the jaw and received surgical and/or conservative treatment. Conclusions: Biological therapies can potentially develop adverse effects in the oral cavity, so strict monitoring by the dentist is necessary.
ISSN:2076-3417
2076-3417
DOI:10.3390/app11114865